Cargando…

α‐Emitting cancer therapy using (211)At‐AAMT targeting LAT1

α‐Methyl‐l‐tyrosine (AMT) has a high affinity for the cancer‐specific l‐type amino acid transporter 1 (LAT1). Therefore, we established an anti‐cancer therapy, with (211)At‐labeled α‐methyl‐l‐tyrosine ((211)At‐AAMT) as a carrier of (211)At into tumors. (211)At‐AAMT had high affinity for LAT1, inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaneda‐Nakashima, Kazuko, Zhang, ZiJian, Manabe, Yoshiyuki, Shimoyama, Atsushi, Kabayama, Kazuya, Watabe, Tadashi, Kanai, Yoshikatsu, Ooe, Kazuhiro, Toyoshima, Atsushi, Shirakami, Yoshifumi, Yoshimura, Takashi, Fukuda, Mitsuhiro, Hatazawa, Jun, Nakano, Takashi, Fukase, Koichi, Shinohara, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935802/ https://www.ncbi.nlm.nih.gov/pubmed/33277750 http://dx.doi.org/10.1111/cas.14761

Ejemplares similares

Targeted alpha therapy using astatine ((211)At)-labeled phenylalanine: A preclinical study in glioma bearing mice
por: Watabe, Tadashi, et al.
Publicado: (2020)

Synthesis of [(211)At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution
por: Shirakami, Yoshifumi, et al.
Publicado: (2021)

Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [(211)At] NaAt in Mice: A Revisit()
por: Liu, Yuwei, et al.
Publicado: (2020)

Enhancement of (211)At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer
por: Watabe, Tadashi, et al.
Publicado: (2019)

Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy
por: Kato, Hiroki, et al.
Publicado: (2021)

Comparison of the Therapeutic Effects of [(211)At]NaAt and [(131)I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model
por: Watabe, Tadashi, et al.
Publicado: (2022)

Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection
por: Huang, Xuhao, et al.
Publicado: (2022)

Extended single-dose toxicity study of [(211)At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer
por: Watabe, Tadashi, et al.
Publicado: (2021)

Effect to Therapy of Sodium-Iodine Symporter Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter
por: Kaneda-Nakashima, Kazuko, et al.
Publicado: (2022)

Targeted α-therapy using astatine ((211)At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound
por: Watabe, Tadashi, et al.
Publicado: (2022)

Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with (211)At Using Implanted Mouse Tumor
por: Yonekura, Yoshiharu, et al.
Publicado: (2022)

Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine
por: Aso, Ayaka, et al.
Publicado: (2023)

Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model
por: Liu, Yuwei, et al.
Publicado: (2021)

Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
por: Watabe, Tadashi, et al.
Publicado: (2023)

Exploring a Nuclear-Selective Radioisotope Delivery System for Efficient Targeted Alpha Therapy
por: Iizuka, Yuki, et al.
Publicado: (2023)

Quantitative measurement of (219)Rn radioactivity in exhaled breath from patients with bone metastasis of castration-resistant prostate cancer treated with (223)RaCl(2)
por: Ooe, Kazuhiro, et al.
Publicado: (2019)

Feasibility studies towards future self-sufficient supply of the (99)Mo-(99m)Tc isotopes with Japanese accelerators
por: NAKAI, Kozi, et al.
Publicado: (2014)

Multi-modal 3D imaging of radionuclides using multiple hybrid Compton cameras
por: Omata, Akihisa, et al.
Publicado: (2022)

Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models
por: Shi, Zitong, et al.
Publicado: (2023)

PB1946: ACQUIRED AMEGAKARYOCYTIC THROMBOCYTOPENA (AAMT), A SINGLE CENTER EXPERIENCE
por: Mohamed, S., et al.
Publicado: (2022)

Dysoticans F–H: three unprecedented dimeric cadinanes from Dysoxylum parasiticum (Osbeck) Kosterm. stem bark
por: Naini, Al Arofatus, et al.
Publicado: (2023)

Performance demonstration of a hybrid Compton camera with an active pinhole for wide-band X-ray and gamma-ray imaging
por: Omata, Akihisa, et al.
Publicado: (2020)

Lipid A-Mediated Bacterial–Host Chemical Ecology: Synthetic Research of Bacterial Lipid As and Their Development as Adjuvants
por: Shimoyama, Atsushi, et al.
Publicado: (2021)

Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor
por: Rii, Junryo, et al.
Publicado: (2021)

Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma
por: Isoda, Atsushi, et al.
Publicado: (2014)

Enhancing the Therapeutic Effect of 2-(211)At-astato-α-methyl-L-phenylalanine with Probenecid Loading
por: Hanaoka, Hirofumi, et al.
Publicado: (2021)

Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB(0,+), LAT1 and LAT2
por: Wongthai, Printip, et al.
Publicado: (2015)

LAT1 expression influences Paneth cell number and tumor development in Apc(Min/+) mice
por: Sui, Yunlong, et al.
Publicado: (2023)

Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor
por: Okanishi, Hiroki, et al.
Publicado: (2020)

Correction: LAT1 expression influences Paneth cell number and tumor development in Apc(Min/+) mice
por: Sui, Yunlong, et al.
Publicado: (2023)

Stabilization of an (211)At-Labeled Antibody with Sodium Ascorbate
por: Manabe, Shino, et al.
Publicado: (2021)

Human dosimetry of free (211)At and meta-[(211)At]astatobenzylguanidine ((211)At-MABG) estimated using preclinical biodistribution from normal mice
por: Ukon, Naoyuki, et al.
Publicado: (2020)

Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
por: Katayama, Daisuke, et al.
Publicado: (2021)

Establishment of Stable Cell Lines With High Expression of Heterodimers of Human 4F2hc and Human Amino Acid Transporter LAT1 or LAT2 and Delineation of Their Differential Interaction With α-Alkyl Moieties
por: Khunweeraphong, Narakorn, et al.
Publicado: (2012)

Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells
por: Nishikubo, Kou, et al.
Publicado: (2022)

Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells
por: Nishikubo, Kou, et al.
Publicado: (2023)

Radioimmunotherapy with an (211)At‐labeled anti–tissue factor antibody protected by sodium ascorbate
por: Takashima, Hiroki, et al.
Publicado: (2021)

Tumor Targeting of (211)At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis
por: Takashima, Hiroki, et al.
Publicado: (2022)

Poly[(μ(2)-2-hydroxy-2-methylpropionato-κ(3) O (1),O (2):O (1′))(μ(2)-2-hydroxy-2-methylpropionato-κ(2) O (1):κO (1′))dioxidouranium(VI)]
por: Yoshimura, Takashi, et al.
Publicado: (2009)

Specific transport of 3‐fluoro‐l‐α‐methyl‐tyrosine by LAT1 explains its specificity to malignant tumors in imaging
por: Wei, Ling, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_45g2o2dcbrvflqjdsvplv5uo9q